Effect of the protein corona on nanoparticles for modulating cytotoxicity and immunotoxicity

International Journal of Nanomedicine

Volumn 10, Issue , 2014, Pages 97-113

  Lee, Yeon Kyung ^a   Choi, Eun Ju ^b   Webster, Thomas J ^c   Kim, Sang Hyun ^d   Khang, Dongwoo ^a  

^a Gachon University   (South Korea)

^b Konkuk University   (South Korea)

^c Northeastern University   (United States)

^d Kyungpook National University School of Medicine   (South Korea)

Author keywords

Blood response; Cytotoxicity; Immunotoxicity; Nanostructured biomaterials; Protein corona

Indexed keywords

APOLIPOPROTEIN A1; BIOMATERIAL; FIBRINOGEN; HUMAN SERUM ALBUMIN; NANOPARTICLE; PLASMA PROTEIN; PROTEIN; PROTEIN CORONA; UNCLASSIFIED DRUG;

ADSORPTION; CONFORMATIONAL TRANSITION; CYTOTOXICITY; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOTOXICITY; IN VIVO STUDY; PROTEIN ANALYSIS; PROTEIN INTERACTION; PROTEIN MODIFICATION; PROTEIN STRUCTURE; REVIEW; ACTIVE IMMUNIZATION; CELL SURVIVAL; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; METABOLISM; SURFACE PROPERTY; TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL;

BLOOD PROTEINS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG DELIVERY SYSTEMS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IMMUNITY, ACTIVE; NANOPARTICLES; PROTEIN CORONA; SURFACE PROPERTIES;

EID: 84919687408     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S72998     Document Type: Review

References (71)

1. De M, Ghosh P, Rotello V. Applications of nanoparticles in biology. Adv Mater. 2008;20:4225-4241.
2. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer. 2005;5(3):161-171.
3. Stephan MT, Moon JJ, Um SH, Bershteyn A, Irvine DJ. Therapeutic cell engineering with surface-conjugated synthetic nanoparticles. Nat Med. 2010;16(9):1035-1041.
4. Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther. 2008;83(5):761-769.
5. Mause SF, Weber C. Microparticles: protagonists of a novel communication network for intercellular information exchange. Circ Res. 2010;107(9):1047-1057.
6. Rak J. Microparticles in cancer. Semin Thromb Hemost. 2010;36(8):888-906.
7. Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Torchilin V, Langer R. Biodegradable long-circulating polymeric nanospheres. Science. 1994;263(5153):1600-1603.
8. Göppert TM, Müller RH. Polysorbate-stabilized solid lipid nanoparticles as colloidal carriers for intravenous targeting of drugs to the brain: comparison of plasma protein adsorption patterns. J Drug Target. 2005;13(3):179-187.
9. Walczyk D, Bombelli FB, Monopoli MP, Lynch I, Dawson KA. What the cell "sees" in bionanoscience. J Am Chem Soc. 2010;132(16):5761-5768.
10. Yan Y, Gause KT, Kamphuis MM, et al. Differential roles of the protein corona in the cellular uptake of nanoporous polymer particles by monocyte and macrophage cell lines. ACS Nano. 2013;23:7(12):10960-10970.
11. Leu D, Manthey B, Kreuter J, Speiser P, DeLuca PP. Distribution and elimination of coated polymethyl [2-14C]methacrylate nanoparticles after intravenous injection in rats. J Pharm Sci. 1984;73(10):1433-1437.
12. Bala I, Hariharan S, Kumar MN. PLGA nanoparticles in drug delivery: the state of the art. Crit Rev Ther Drug Carrier Syst. 2004;21(5):387-422.
13. Lesniak A, Fenaroli F, Monopoli MP, Åberg C, Dawson KA, Salvati A. Effects of the presence or absence of a protein corona on silica nanoparticle uptake and impact on cells. ACS Nano. 2012;6(7):5845-5857.
14. Lesniak A, Salvati A, Santos-Martinez MJ, Radomski MW, Dawson KA, Åberg C. Nanoparticle adhesion to the cell membrane and its effect on nanoparticle uptake efficiency. J Am Chem Soc. 2013;135(4):1438-1444.
15. Treuel L, Brandholt S, Maffre P, Wiegele S, Shang L, Nienhaus GU. Impact of protein modification on the protein corona on nanoparticles and nanoparticle-cell interactions. ACS Nano. 2014;8(1):503-513.
16. Hu W, Peng C, Lv M, et al. Protein corona-mediated mitigation of cytotoxicity of graphene oxide. ACS Nano. 2011;5(5):3693-3700.
17. Yang ST, Liu Y, Wang YW, Cao A. Biosafety and bioapplication of nanomaterials by designing protein-nanoparticle interactions. Small. 2013;9(9-10):1635-1653.
18. Walkey CD, Chan WC. Understanding and controlling the interaction of nanomaterials with proteins in a physiological environment. Chem Soc Rev. 2012;41(7):2780-2799.
19. Fenoglio I, Fubini B, Ghibaudi EM, Turci F. Multiple aspects of the interaction of biomacromolecules with inorganic surfaces. Adv Drug Deliv Rev. 2011;63(13):1186-1209.
20. Monopoli MP, Aberg C, Salvati A, Dawson KA. Biomolecular coronas provide the biological identity of nanosized materials. Nat Nanotechnol. 2012;7(12):779-786.
21. Nel AE, Mädler L, Velegol D, et al. Understanding biophysicochemical interactions at the nano-bio interface. Nat Mater. 2009;8(7):543-557.
22. Wang X, Reece SP, Brown JM. Immunotoxicological impact of engineered nanomaterial exposure: mechanisms of immune cell modulation. Toxicol Mech Methods. 2013;23(3):168-177.
23. Karmali PP, Simberg D. Interactions of nanoparticles with plasma proteins: implication on clearance and toxicity of drug delivery systems. Expert Opin Drug Deliv. 2011;8(3):343-357.
24. Cedervall T, Lynch I, Lindman S, et al. Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles. Proc Natl Acad Sci U S A. 2007;104(7):2050-2055.
25. Monopoli MP, Walczyk D, Campbell A, et al. Physical-chemical aspects of protein corona: relevance to in vitro and in vivo biological impacts of nanoparticles. J Am Chem Soc. 2011;133(8):2525-2534.
26. Peracchia MT, Harnisch S, Pinto-Alphandary H, et al. Visualization of in vitro protein-rejecting properties of PEGylated stealth polycyanoacrylate nanoparticles. Biomaterials. 1999;20(14):1269-1275.
27. Gref R, Lück M, Quellec P, et al. 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf B Biointerfaces. 2000;18(3-4):301-313.
28. Gessner A, Waicz R, Lieske A, Paulke B, Mäder K, Müller RH. Nanoparticles with decreasing surface hydrophobicities: influence on plasma protein adsorption. Int J Pharm. 2000;196(2):245-249.
29. Gessner A, Lieske A, Paulke BR, Müller RH. Functional groups on polystyrene model nanoparticles: influence on protein adsorption. J Biomed Mater Res A. 2003;65(3):319-326.
30. Lacerda SH, Park JJ, Meuse C, et al. Interaction of gold nanoparticles with common human blood proteins. ACS Nano. 2010;4(1):365-379.
31. Casals E, Pfaller T, Duschl A, Oostingh GJ, Puntes V. Time evolution of the nanoparticle protein corona. ACS Nano. 2010;4(7):3623-3632.
32. Miclăuş T, Bochenkov VE, Ogaki R, Howard KA, Sutherland DS. Spatial mapping and quantification of soft and hard protein coronas at silver nanocubes. Nano Lett. 2014;14(4):2086-2093.
33. Medintz IL, Konnert JH, Clapp AR, et al. A fluorescence resonance energy transfer-derived structure of a quantum dot-protein bioconjugate nanoassembly. Proc Natl Acad Sci U S A. 2004;101(26):9612-9617.
34. Aubin-Tam ME, Hamad-Schifferli K. Gold nanoparticle-cytochrome C complexes: the effect of nanoparticle ligand charge on protein structure. Langmuir. 2005;21(26):12080-12084.
35. Roach P, Farrar D, Perry CC. Surface tailoring for controlled protein adsorption: effect of topography at the nanometer scale and chemistry. J Am Chem Soc. 2006;128(12):3939-3945.
36. Lundqvist M, Stigler J, Elia G, Lynch I, Cedervall T, Dawson KA. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc Natl Acad Sci U S A. 2008;105(38):14265-14270.
37. Tenzer S, Docter D, Kuharev J, et al. Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. Nat Nanotechnol. 2013;8(10):772-781.
38. De Paoli SH, Diduch LL, Tegegn TZ, et al. The effect of protein corona composition on the interaction of carbon nanotubes with human blood platelets. Biomaterials. 2014;35(24):6182-6194.
39. Hühn D, Kantner K, Geidel C, et al. Polymer-coated nanoparticles interacting with proteins and cells: focusing on the sign of the net charge. ACS Nano. 2013;7(4):3253-3263.
40. Lacerda L, Bianco A, Prato M, Kostarelos K. Carbon nanotubes as nanomedicines: from toxicology to pharmacology. Adv Drug Deliv Rev. 2006;58(14):1460-1470.
41. Liu Z, Robinson JT, Tabakman SM, Yang K, Dai H. Carbon materials for drug delivery and cancer therapy. Mater Today. 2011;14(7-8):316-323.
42. Cai X, Ramalingam R, Wong HS, et al. Characterization of carbon nanotube protein corona by using quantitative proteomics. Nanomedicine (Lond). 2013;9(5):583-593.
43. Ge C, Du J, Zhao L, et al. Binding of blood proteins to carbon nanotubes reduces cytotoxicity. Proc Natl Acad Sci U S A. 2011;108(41):16968-16973.
44. Zhu Y, Li W, Li Q, et al. Effects of serum proteins on intracellular uptake and cytotoxicity of carbon nanoparticles. Carbon. 2009;47(5):1351-1358.
45. Park SJ, Khang D. Conformational changes of fibrinogen in dispersed carbon nanotubes. Int J Nanomedicine. 2012;7:4325-4333.
46. Mao HY, Laurent S, Chen W, et al. Graphene: promises, facts, opportunities, and challenges in nanomedicine. Chem Rev. 2013;113(5):3407-3424.
47. Mao H, Chen W, Laurent S, et al. Hard corona composition and cellular toxicities of the graphene sheets. Colloids Surf B Biointerfaces. 2013;109:212-218.
48. Lemarchand C, Gref R, Passirani C, et al. Influence of polysaccharide coating on the interactions of nanoparticles with biological systems. Biomaterials. 2006;27(1):108-118.
49. 2) nanoparticles. Small. 2011;7(24):3479-3486.
50. Braydich-Stolle L, Hussain S, Schlager JJ, Hofmann MC. In vitro cytotoxicity of nanoparticles in mammalian germline stem cells. Toxicol Sci. 2005;88(2):412-419.
51. AshaRani PV, Low Kah Mun G, Hande MP, Valiyaveettil S. Cytotoxicity and genotoxicity of silver nanoparticles in human cells. ACS Nano. 2009;3(2):279-290.
52. Kittler S, Greulich C, Diendorf J, Köller M, Epple M. Toxicity of Silver Nanoparticles Increases during Storage Because of Slow Dissolution under Release of Silver Ions. Chem Mater. 2010;22(16):4548-4554.
53. Maiorano G, Sabella S, Sorce B, Brunetti V, Malvindi MA, Cingolani R, Pompa PP. Effects of cell culture media on the dynamic formation of protein-nanoparticle complexes and influence on the cellular response. ACS Nano. 2010;4(12):7481-7491.
54. Lynch I, Salvati A, Dawson KA. Protein-nanoparticle interactions: What does the cell see? Nat Nanotechnol. 2009;4(9):546-547.
55. Müller KH, Motskin M, Philpott AJ, et al. The effect of particle agglomeration on the formation of a surface-connected compartment induced by hydroxyapatite nanoparticles in human monocyte-derived macrophages. Biomaterials. 2014;35(3):1074-1088.
56. Motskin M, Müller KH, Genoud C, Monteith AG, Skepper JN. The sequestration of hydroxyapatite nanoparticles by human monocyte-macrophages in a compartment that allows free diffusion with the extracellular environment. Biomaterials. 2011;32(35):9470-9482.
57. Salmon JE, Kapur S, Kimberly RP. Opsonin-independent ligation of Fc gamma receptors. The 3G8-bearing receptors on neutrophils mediate the phagocytosis of concanavalin A-treated erythrocytes and nonopsonized Escherichia coli. J Exp Med. 1987;166(6):1798-1813.
58. Harashima H, Sakata K, Funato K, Kiwada H. Enhanced hepatic uptake of liposomes through complement activation depending on the size of liposomes. Pharm Res. 1994;11(3):402-406.
59. Leroux JC, De Jaeghere F, Anner B, Doelker E, Gurny R. An investigation on the role of plasma and serum opsonins on the internalization of biodegradable poly(D,L-lactic acid) nanoparticles by human monocytes. Life Sci. 1995;57(7):695-703.
60. Sim RB, Tsiftsoglou SA. Proteases of the complement system. Biochem Soc Trans. 2004;32(Pt 1):21-27.
61. Rybak-Smith MJ, Sim RB; Rybak-Smith MJ. Complement activation by carbon nanotubes. Adv Drug Deliv Rev. 2011;63(12):1031-1041.
62. Bertholon I, Vauthier C, Labarre D. Complement activation by core-shell poly(isobutylcyanoacrylate)-polysaccharide nanoparticles: influences of surface morphology, length, and type of polysaccharide. Pharm Res. 2006;23(6):1313-1323.
63. Hulander M, Lundgren A, Berglin M, Ohrlander M, Lausmaa J, Elwing H. Immune complement activation is attenuated by surface nanotopography. Int J Nanomedicine. 2011;6:2653-2666.
64. Gorbet MB, Sefton MV. Biomaterial-associated thrombosis: roles of coagulation factors, complement, platelets and leukocytes. Biomaterials. 2004;25(26):5681-5703.
65. Salvador-Morales C, Flahaut E, Sim E, Sloan J, Green ML, Sim RB, Salvador-Morales C. Complement activation and protein adsorption by carbon nanotubes. Mol Immunol. 2006;43(3):193-201.
66. Kouser L, Abdul-Aziz M, Nayak A, Stover CM, Sim RB, Kishore U. Properdin and factor h: opposing players on the alternative complement pathway "see-saw". Front Immunol. 2013;4:93.
67. Horbett T. Chapter 13 Principles underlying the role of adsorbed plasma proteins in blood interactions with foreign materials. Cardiovasc Pathol. 1993;2(3):137-148.
68. Chinn JA, Horbett TA, Ratner BD. Baboon fibrinogen adsorption and platelet adhesion to polymeric materials. Thromb Haemost. 1991;65(5):608-617.
69. Lishko VK, Podolnikova NP, Yakubenko VP, et al. Multiple binding sites in fibrinogen for integrin alphaMbeta2 (Mac-1). J Biol Chem. 2004 22;279(43):44897-44906.
70. Ding ZM, Babensee JE, Simon SI, et al. Relative contribution of LFA-1 and Mac-1 to neutrophil adhesion and migration. J Immunol. 1999;163(9):5029-5038.
71. Deng ZJ, Liang M, Monteiro M, Toth I, Minchin RF. Nanoparticle-induced unfolding of fibrinogen promotes Mac-1 receptor activation and inflammation. Nat Nanotechnol. 2011;6(1):39-44.